Immutep Ltd - ROE
PRRUF
Price:
$0.05
Market Cap:
$69.26M
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinom...[Read more]
Industry
Biotechnology
IPO Date
2012-02-22
Stock Exchange
OTC
Ticker
PRRUF
PE Ratio
[-1.72]
ROE
[-69.20%]
Current Ratio
[2.97]
Dividend Yield
[0%]
Enterprise Value
[-1323749.00]
Dividend History
The ROE as of August 2026 (TTM) for Immutep Ltd (PRRUF) is -69.20%
According to Immutep Ltd’s latest financial reports and current stock price. The company's current ROE is -69.20%. This represents a change of 185.76% compared to the average of -24.22% of the last 4 quarters.
Immutep Ltd (PRRUF) Historical ROE (quarterly & annually)
How has PRRUF ROE performed in the past?
The mean historical ROE of Immutep Ltd over the last ten years is -52.57%. The current -69.20% ROE has changed 31.64% with respect to the historical average. Over the past ten years (40 quarters), PRRUF's ROE was at its highest in in the December 2007 quarter at 0%. The ROE was at its lowest in in the December 2015 quarter at -138.26%.
Average
-52.57%
Median
-39.23%
Minimum
-175.59%
Maximum
-22.54%
Immutep Ltd (PRRUF) ROE by Quarter and Year
Discovering the peaks and valleys of Immutep Ltd ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 89.76%
Maximum Annual ROE = -22.54%
Minimum Annual Increase = -79.89%
Minimum Annual ROE = -175.59%
| Year | ROE | Change |
|---|---|---|
| 2025 | -42.77% | 89.76% |
| 2024 | -22.54% | -22.90% |
| 2023 | -29.23% | -14.62% |
| 2022 | -34.24% | -16.10% |
| 2021 | -40.81% | 0.90% |
| 2020 | -40.45% | -39.38% |
| 2019 | -66.72% | 75.46% |
| 2018 | -38.02% | 7.70% |
| 2017 | -35.30% | -79.89% |
| 2016 | -175.59% | 34.84% |
Immutep Ltd (PRRUF) Average ROE
How has PRRUF ROE performed in the past?
The current ROE of Immutep Ltd (PRRUF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-31.51%
5-year avg
-33.92%
10-year avg
-52.57%
Immutep Ltd (PRRUF) ROE vs. Peers
How is PRRUF’s ROE compared to its peers?
Immutep Ltd’s ROE is greater than Cellectis S.A. (-80.61%), less than CytoDyn Inc. (36.98%), greater than Transgene S.A. (-63.53%), less than Northwest Biotherapeutics, Inc. (62.41%), less than Clinuvel Pharmaceuticals Limited (13.29%), less than Hansa Biopharma AB (213.16%), less than Frontage Holdings Corporation (1.98%), less than Clinuvel Pharmaceuticals Limited (13.29%), greater than Healios K.K. (-75.40%), greater than Silence Therapeutics plc (-121.71%),
| Company | ROE | Market cap |
|---|---|---|
| -80.61% | $251.93M | |
| 36.98% | $258.74M | |
| -63.53% | $122.57M | |
| 62.41% | $263.10M | |
| 13.29% | $329.69M | |
| 213.16% | $369.01M | |
| 1.98% | $304.16M | |
| 13.29% | $345.27M | |
| -75.40% | $243.00M | |
| -121.71% | $212.56M |
Build a custom stock screener for Immutep Ltd (PRRUF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immutep Ltd using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Immutep Ltd (PRRUF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Immutep Ltd or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Immutep Ltd's ROE?
How is the ROE calculated for Immutep Ltd (PRRUF)?
What is the highest ROE for Immutep Ltd (PRRUF)?
What is the 3-year average ROE for Immutep Ltd (PRRUF)?
What is the 5-year average ROE for Immutep Ltd (PRRUF)?
How does the current ROE for Immutep Ltd (PRRUF) compare to its historical average?